Helix Acquisition Corp II
HLXB9.900USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
232.74MMarket Cap
48.70P/E TTM
More Details of Helix Acquisition Corp II Company
Helix Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to as its initial business combination. The Company has not selected any specific business combination target and it has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination. While it may pursue a business combination target in any business or industry, it intends to focus on healthcare or healthcare related industries. The Company has not generated any revenue.
Helix Acquisition Corp II Info
Ticker SymbolHLXB
Company nameHelix Acquisition Corp II
IPO dateFeb 09, 2024
CEOMs. Bihua Chen
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 09
AddressC/O Cormorant Asset Management, Lp
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02116
Phone18577020377
Website
Ticker SymbolHLXB
IPO dateFeb 09, 2024
CEOMs. Bihua Chen
Company Executives of Helix Acquisition Corp II
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
Other
43.73%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
22.35%
BridgeBio Pharma, Inc.
18.24%
Deerfield Management Company, L.P.
6.11%
BC Global Opportunities IX LP
5.46%
Omega Fund Management, LLC
4.11%
Other
43.73%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.69%
Corporation
26.98%
Investment Advisor/Hedge Fund
10.78%
Venture Capital
10.12%
Investment Advisor
5.17%
Research Firm
0.26%
Individual Investor
0.11%
Other
4.88%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
53
37.59M
47.47%
+19.96M
2025Q2
45
24.80M
131.18%
+8.09M
2025Q1
44
17.89M
94.60%
+829.91K
2024Q4
41
17.82M
94.24%
+1.30M
2024Q3
37
17.47M
92.41%
+1.09M
2024Q2
35
17.48M
94.85%
+1.41M
2024Q1
33
17.17M
90.80%
+8.90M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
17.88M
22.57%
+14.97M
+514.60%
Aug 29, 2025
BridgeBio Pharma, Inc.
13.81M
17.43%
+13.81M
--
Aug 29, 2025
Deerfield Management Company, L.P.
4.89M
6.17%
+4.89M
--
Aug 29, 2025
BC Global Opportunities IX LP
4.37M
5.51%
+3.27M
+296.89%
Sep 04, 2025
Citadel Advisors LLC
1.43M
1.8%
+15.24K
+1.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
0.26%
Schwab U.S. Small-Cap ETF
0.01%
iShares Health Innovation Active ETF
0%
Schwab U.S. Broad Market ETF
0%
Tema Oncology ETF
Proportion0.26%
Schwab U.S. Small-Cap ETF
Proportion0.01%
iShares Health Innovation Active ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Helix Acquisition Corp II?
The top five shareholders of Helix Acquisition Corp II are:
Cormorant Asset Management, LP holds 17.88M shares, accounting for 22.57% of the total shares.
BridgeBio Pharma, Inc. holds 13.81M shares, accounting for 17.43% of the total shares.
Deerfield Management Company, L.P. holds 4.89M shares, accounting for 6.17% of the total shares.
BC Global Opportunities IX LP holds 4.37M shares, accounting for 5.51% of the total shares.
Citadel Advisors LLC holds 1.43M shares, accounting for 1.80% of the total shares.
Cormorant Asset Management, LP holds 17.88M shares, accounting for 22.57% of the total shares.
BridgeBio Pharma, Inc. holds 13.81M shares, accounting for 17.43% of the total shares.
Deerfield Management Company, L.P. holds 4.89M shares, accounting for 6.17% of the total shares.
BC Global Opportunities IX LP holds 4.37M shares, accounting for 5.51% of the total shares.
Citadel Advisors LLC holds 1.43M shares, accounting for 1.80% of the total shares.
What are the top three shareholder types of Helix Acquisition Corp II?
The top three shareholder types of Helix Acquisition Corp II are:
Cormorant Asset Management, LP
BridgeBio Pharma, Inc.
Deerfield Management Company, L.P.
Cormorant Asset Management, LP
BridgeBio Pharma, Inc.
Deerfield Management Company, L.P.
How many institutions hold shares of Helix Acquisition Corp II (HLXB)?
As of 2025Q3, 53 institutions hold shares of Helix Acquisition Corp II, with a combined market value of approximately 37.59M, accounting for 47.47% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -83.71%.
What is the biggest source of revenue for Helix Acquisition Corp II?
In --, the -- business generated the highest revenue for Helix Acquisition Corp II, amounting to -- and accounting for --% of total revenue.
